These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 31196609)

  • 21. STIM promotes the epithelial-mesenchymal transition of podocytes through regulation of FcγRII activity in diabetic nephropathy.
    Jin J; Ye M; Hu K; Gong J; He Q
    Histol Histopathol; 2019 Jun; 34(6):671-682. PubMed ID: 30475382
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabolomics as a tool for the early diagnosis and prognosis of diabetic kidney disease.
    Pereira PR; Carrageta DF; Oliveira PF; Rodrigues A; Alves MG; Monteiro MP
    Med Res Rev; 2022 Jul; 42(4):1518-1544. PubMed ID: 35274315
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rotten to the Cortex: Ceramide-Mediated Lipotoxicity in Diabetic Kidney Disease.
    Nicholson RJ; Pezzolesi MG; Summers SA
    Front Endocrinol (Lausanne); 2020; 11():622692. PubMed ID: 33584550
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Mitochondria-Targeted Metabolic Tubular Injury in Diabetic Kidney Disease.
    Jiang H; Shao X; Jia S; Qu L; Weng C; Shen X; Wang Y; Huang H; Wang Y; Wang C; Feng S; Wang M; Feng H; Geekiyanage S; Davidson AJ; Chen J
    Cell Physiol Biochem; 2019; 52(2):156-171. PubMed ID: 30816665
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular Mechanisms in Early Diabetic Kidney Disease: Glomerular Endothelial Cell Dysfunction.
    Lassén E; Daehn IS
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33322614
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Histone demethylase UTX is a therapeutic target for diabetic kidney disease.
    Chen H; Huang Y; Zhu X; Liu C; Yuan Y; Su H; Zhang C; Liu C; Xiong M; Qu Y; Yun P; Zheng L; Huang K
    J Physiol; 2019 Mar; 597(6):1643-1660. PubMed ID: 30516825
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Markers of and risk factors for the development and progression of diabetic kidney disease.
    Macisaac RJ; Ekinci EI; Jerums G
    Am J Kidney Dis; 2014 Feb; 63(2 Suppl 2):S39-62. PubMed ID: 24461729
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diabetic kidney diseases revisited: A new perspective for a new era.
    Fu H; Liu S; Bastacky SI; Wang X; Tian XJ; Zhou D
    Mol Metab; 2019 Dec; 30():250-263. PubMed ID: 31767176
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A NOX4/TRPC6 Pathway in Podocyte Calcium Regulation and Renal Damage in Diabetic Kidney Disease.
    Ilatovskaya DV; Blass G; Palygin O; Levchenko V; Pavlov TS; Grzybowski MN; Winsor K; Shuyskiy LS; Geurts AM; Cowley AW; Birnbaumer L; Staruschenko A
    J Am Soc Nephrol; 2018 Jul; 29(7):1917-1927. PubMed ID: 29793963
    [No Abstract]   [Full Text] [Related]  

  • 30. Update of pathophysiology and management of diabetic kidney disease.
    Lin YC; Chang YH; Yang SY; Wu KD; Chu TS
    J Formos Med Assoc; 2018 Aug; 117(8):662-675. PubMed ID: 29486908
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of oxidative stress in diabetic kidney disease.
    Hakim FA; Pflueger A
    Med Sci Monit; 2010 Feb; 16(2):RA37-48. PubMed ID: 20110930
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of Diabetic Kidney Disease: Current and Future.
    Yamazaki T; Mimura I; Tanaka T; Nangaku M
    Diabetes Metab J; 2021 Jan; 45(1):11-26. PubMed ID: 33508907
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diabetes-related end-stage renal disease in Austria 1965-2013.
    Prischl FC; Auinger M; Säemann M; Mayer G; Rosenkranz AR; Wallner M; Kramar R;
    Nephrol Dial Transplant; 2015 Nov; 30(11):1920-7. PubMed ID: 25977308
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mechanisms of metabolic memory and renal hypoxia as a therapeutic target in diabetic kidney disease.
    Hirakawa Y; Tanaka T; Nangaku M
    J Diabetes Investig; 2017 May; 8(3):261-271. PubMed ID: 28097824
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glomerular cell cross talk in diabetic kidney diseases.
    Dong R; Xu Y
    J Diabetes; 2022 Aug; 14(8):514-523. PubMed ID: 35999686
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intestinal microbiome diversity of diabetic and non-diabetic kidney disease: Current status and future perspective.
    Das S; Gnanasambandan R
    Life Sci; 2023 Mar; 316():121414. PubMed ID: 36682521
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diabetic Kidney Disease: An Update.
    Gupta S; Dominguez M; Golestaneh L
    Med Clin North Am; 2023 Jul; 107(4):689-705. PubMed ID: 37258007
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The roles of sodium-glucose cotransporter 2 inhibitors in preventing kidney injury in diabetes.
    Jaikumkao K; Pongchaidecha A; Chatsudthipong V; Chattipakorn SC; Chattipakorn N; Lungkaphin A
    Biomed Pharmacother; 2017 Oct; 94():176-187. PubMed ID: 28759755
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synopsis of Sweet! Mouse Models of Diabetic Kidney Disease.
    Heinz-Taheny KM; Harlan SM; Qi Z; Heuer JG
    Toxicol Pathol; 2018 Dec; 46(8):970-975. PubMed ID: 30213245
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regulation of autophagy by natural polyphenols in the treatment of diabetic kidney disease: therapeutic potential and mechanism.
    Liu T; Jin Q; Yang L; Mao H; Ma F; Wang Y; Li P; Zhan Y
    Front Endocrinol (Lausanne); 2023; 14():1142276. PubMed ID: 37635982
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.